Bryant R England1, Huifeng Yun2, Lang Chen2, Jared Vanderbleek2, Kaleb Michaud3, Ted R Mikuls1, Jeffrey R Curtis2. 1. University of Nebraska Medical Center and Veterans Administration Nebraska-Western Iowa Health Care System, Omaha. 2. University of Alabama at Birmingham. 3. FORWARD, The National Databank for Rheumatic Diseases, Wichita, Kansas, and University of Nebraska Medical Center and Veterans Administration Nebraska-Western Iowa Health Care System, Omaha.
Abstract
OBJECTIVE: To determine whether multimorbidity is associated with treatment changes and achieving target disease activity thresholds in patients with active rheumatoid arthritis (RA). METHODS: We conducted a retrospective cohort study of adults with active RA within the Rheumatology Informatics System for Effectiveness (RISE) registry. Multimorbidity was measured using RxRisk, a medication-based index of chronic disease. We used multivariable logistic regression models to assess the associations of multimorbidity with the odds of initiating a new disease-modifying antirheumatic drug (DMARD) in active RA, and among those initiating a new DMARD, the odds of achieving low disease activity or remission. RESULTS: We identified 15,626 patients using the Routine Assessment of Patient Index Data 3 (RAPID3) cohort and 5,733 patients using the Clinical Disease Activity Index (CDAI) cohort. All patients had active RA, of which 1,558 (RAPID3) and 834 (CDAI) initiated a new DMARD and had follow-up disease activity measures. Patients were middle aged, female, and predominantly White, and on average received medications from 6 to 7 RxRisk categories. Multimorbidity was not associated with new DMARD initiation in active RA. However, a greater burden of multimorbidity was associated with lower odds of achieving treatment targets (per 1-unit RxRisk: RAPID3 cohort odds ratio [OR] 0.95 [95% confidence interval (95% CI) 0.91, 0.98]; CDAI cohort OR 0.94 [95% CI 0.90, 0.99]). Those with the highest burden of multimorbidity had the lowest odds of achieving target RA disease activity (RAPID3 cohort OR 0.54 [95% CI 0.34, 0.85]; CDAI cohort OR 0.65 [95% CI 0.37, 1.15]). CONCLUSION: These findings from a large, real-world registry illustrate the potential impact of multimorbidity on treatment response and indicate that a more holistic management approach targeting multimorbidity may be needed to optimize RA disease control in these patients.
OBJECTIVE: To determine whether multimorbidity is associated with treatment changes and achieving target disease activity thresholds in patients with active rheumatoid arthritis (RA). METHODS: We conducted a retrospective cohort study of adults with active RA within the Rheumatology Informatics System for Effectiveness (RISE) registry. Multimorbidity was measured using RxRisk, a medication-based index of chronic disease. We used multivariable logistic regression models to assess the associations of multimorbidity with the odds of initiating a new disease-modifying antirheumatic drug (DMARD) in active RA, and among those initiating a new DMARD, the odds of achieving low disease activity or remission. RESULTS: We identified 15,626 patients using the Routine Assessment of Patient Index Data 3 (RAPID3) cohort and 5,733 patients using the Clinical Disease Activity Index (CDAI) cohort. All patients had active RA, of which 1,558 (RAPID3) and 834 (CDAI) initiated a new DMARD and had follow-up disease activity measures. Patients were middle aged, female, and predominantly White, and on average received medications from 6 to 7 RxRisk categories. Multimorbidity was not associated with new DMARD initiation in active RA. However, a greater burden of multimorbidity was associated with lower odds of achieving treatment targets (per 1-unit RxRisk: RAPID3 cohort odds ratio [OR] 0.95 [95% confidence interval (95% CI) 0.91, 0.98]; CDAI cohort OR 0.94 [95% CI 0.90, 0.99]). Those with the highest burden of multimorbidity had the lowest odds of achieving target RA disease activity (RAPID3 cohort OR 0.54 [95% CI 0.34, 0.85]; CDAI cohort OR 0.65 [95% CI 0.37, 1.15]). CONCLUSION: These findings from a large, real-world registry illustrate the potential impact of multimorbidity on treatment response and indicate that a more holistic management approach targeting multimorbidity may be needed to optimize RA disease control in these patients.
Authors: Kevin L Sloan; Anne E Sales; Chuan-Fen Liu; Paul Fishman; Paul Nichol; Norman T Suzuki; Nancy D Sharp Journal: Med Care Date: 2003-06 Impact factor: 2.983
Authors: Helga Radner; Kazuki Yoshida; Maria Dahl Mjaavatten; Daniel Aletaha; Michelle Frits; Bing Lu; Christine Iannaccone; Nancy Shadick; Michael Weinblatt; Ihsane Hmamouchi; M Dougados; Josef S Smolen; Daniel H Solomon Journal: Semin Arthritis Rheum Date: 2015-06-19 Impact factor: 5.532
Authors: Kazuki Yoshida; Tzu-Chieh Lin; Melissa Y Wei; Susan Malspeis; Su H Chu; Carlos A Camargo; Benjamin A Raby; Hyon K Choi; Sara K Tedeschi; Medha Barbhaiya; Bing Lu; Karen H Costenbader; Elizabeth W Karlson; Jeffrey A Sparks Journal: Arthritis Care Res (Hoboken) Date: 2021-02 Impact factor: 4.794
Authors: Daniel Aletaha; Valerie P K Nell; Tanja Stamm; Martin Uffmann; Stephan Pflugbeil; Klaus Machold; Josef S Smolen Journal: Arthritis Res Ther Date: 2005-04-07 Impact factor: 5.156
Authors: Tore K Kvien; Alejandro Balsa; Neil Betteridge; Maya H Buch; Patrick Durez; Ennio Giulio Favalli; Guillaume Favier; Cem Gabay; Rinie Geenen; Ioanna Gouni-Berthold; Frank van den Hoogen; Alison Kent; Lars Klareskog; Mikkel Ostergaard; Karel Pavelka; Joaquim Polido Pereira; Anne Grete Semb; Magnus Sköld; Maxime Dougados Journal: RMD Open Date: 2020-07
Authors: Marloes Vermeer; Hillechiena H Kuper; Hein J Bernelot Moens; Monique Hoekstra; Marcel D Posthumus; Piet L C M van Riel; Mart A F J van de Laar Journal: Arthritis Res Ther Date: 2012-11-23 Impact factor: 5.156